Active Stocks
Tue Mar 19 2024 15:58:41
  1. Tata Consultancy Services share price
  2. 3,977.55 -4.03%
  1. Tata Steel share price
  2. 148.65 -0.64%
  1. Bharti Airtel share price
  2. 1,227.85 0.23%
  1. Power Grid Corporation Of India share price
  2. 258.95 -2.28%
  1. ITC share price
  2. 409.50 -1.89%
Business News/ News / India/  Novavax covid-19 vaccine shows 90% efficacy in US phase 3 trial
BackBack

Novavax covid-19 vaccine shows 90% efficacy in US phase 3 trial

India expects around 200 million doses to be supplied to it in August-December
  • The covid-19 vaccine is being contract manufactured under the Covovax brand by Serum Institute of India
  • The strong efficacy was analysed at a time when the B.1.1.7 ‘alpha’ variant of the novel coronavirus, first found in the UK, was the dominant strain in the US. (AP)Premium
    The strong efficacy was analysed at a time when the B.1.1.7 ‘alpha’ variant of the novel coronavirus, first found in the UK, was the dominant strain in the US. (AP)

    NEW DELHI : Novavax on Monday released an interim analysis from its ongoing phase 3 trial in the US and Mexico, which showed that its covid-19 vaccine candidate had an efficacy of 90%. The vaccine is being contract manufactured under the Covovax brand by Serum Institute of India, which is currently conducting a bridging study in India.

    “Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines," Novavax president and chief executive officer (CEO) Stanley C. Erck said.

    The efficacy results come at a time developed countries have vaccinated a most, if not a majority, of their population. The US, Canada, the UK, France and Germany have administered at least one dose of a vaccine to 44-64% of their population, according to Our World in Data. In the US and UK, where the trial was conducted, about 43% of their respective populations have been fully vaccinated, while a majority have got at least one dose of either Pfizer, Moderna, AstraZeneca or Johnson and Johnson’s vaccines.

    At an investor conference call following the results, Erck said the company will initially focus on low-and middle-income countries, including India, supplying 1.1 billion doses through the Covax initiative.

    “In the very early days, it’s going to be low- and middle-income countries, and throughout 2022, I think, there is going to be a transition from satisfying the 1.1 billion dose commitment to Covax into (providing developed countries) a booster... I think, particularly in the US, our vaccine is going to be used as a booster," Erck added.

    Erck said the company plans to file for a regulatory clearance in India, along with US, UK and European Union by the end of the second quarter—a timeline that has also been given by Adar Poonawalla, the CEO of Serum Institute.

    The Indian government anticipates around 200 million Covovax doses to be supplied to it by Serum Institute in August-December, making the vaccine one of the major vaccines in the pipeline for the country.

    The phase 3 trial in the US and Mexico showed the vaccine had an overall efficacy of 90.4% in a group of 29,960 participants . Two-thirds of the participants were given the vaccine while the rest were given a placebo. Across the two groups, 77 cases of covid were observed between 25 January and 30 April—63 in the placebo group and 14 in the vaccine group—yielding an efficacy of 90.4%.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 14 Jun 2021, 06:08 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App